SUTRO BIOPHARMA, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 |
|---|---|---|---|
| Revenue | $38.4M | $51.7M | $59.7M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $54.3M | $54.6M | $43.6M |
| SG&A Expense | $21.4M | $16.4M | $14.8M |
| Operating Income | $-37.2M | $-19.3M | $1.4M |
| Operating Margin | -96.9% | -37.2% | 2.3% |
| Interest Expense | $1.6M | $612.0K | $0 |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | — |
| Net Income | $-35.3M | $-19.7M | $1.7M |
| Net Margin | -91.9% | -38.1% | 2.8% |
| EPS (Basic) | $-6.13 | $-43.95 | $0.00 |
| EPS (Diluted) | $-6.13 | $-43.95 | $0.00 |
| Shares Outstanding (Basic) | 22.8M | 465.3K | — |
| Shares Outstanding (Diluted) | 22.8M | 465.3K | — |
| Dividends Per Share | — | — | — |